Novavax, Inc. (NASDAQ:NVAX) Analyst Evaluation
Post# of 22755
Novavax, Inc. (NASDAQ:NVAX) currently has mean rating of 2.60 while 1 analysts have commented the shares as ‘BUY’, 1 recommended as ‘OUTPERFORM’ and 6 commented as ‘HOLD’. The rating score is on a scale of 1-5 where 1 stands for strong buy and 5 stands for strong sell. The mean price target for the equity is at $3.50 while the highest price target suggested by the brokerage firms is $12.00 and low price target is $1.50. The mean price target is calculated keeping in view the consensus of 6 analysts.
The mean revenue estimate for the ongoing quarter ending Dec 16 is $5.25M by 7 analysts. The average forecast of sales for the year ending Dec 16 is $15.52M by 6 financial experts.
Novavax, Inc. (NASDAQ:NVAX) went down -0.74% during trading on 12/13/2016, with the company’s shares hitting the price near $1.34. The stock had a trading capacity of 6.2M shares. The firm has a SMA 50 (Simple Moving Average) of -9.90% and a SMA 200-(Simple Moving Average) of -72.22%. This appreciation has taken its market valuation to 363.23M. Shares registered one year high at $8.95 and the one year low of $1.16.
Earnings Summary
In Novavax, Inc. (NASDAQ:NVAX) latest quarter ended on 30 Sep 2016, company revealed earnings of $-0.24 a share. The reported earnings topped the analyst’s consensus by $0.02 with the surprise factor around 7.70%. In the matter of earnings surprises, it can have a huge impact on a company’s stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock’s price, but also to a gradual increase over time.
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'